Lynide 10mg Capsule contains Lenalidomide, an immunomodulatory agent indicated primarily for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. Lenalidomide exerts its therapeutic effects by modulating the immune system, inhibiting angiogenesis, and inducing apoptosis in malignant cells. It is commonly prescribed as part of combination chemotherapy regimens or as monotherapy in patients who have relapsed or are refractory to prior treatments. The 10mg dosage is tailored to optimize efficacy while minimizing adverse effects, which may include neutropenia, thrombocytopenia, fatigue, and gastrointestinal disturbances. Due to its teratogenic potential, strict adherence to pregnancy prevention programs is mandatory for patients of reproductive potential. Regular monitoring of blood counts and renal function is essential during therapy to detect hematologic toxicity and adjust dosing accordingly. Patients should be advised to report any signs of infection, bleeding, or unusual symptoms promptly. Lynide 10mg Capsule should be administered under the supervision of a healthcare professional experienced in oncology, ensuring appropriate patient selection and management to maximize therapeutic outcomes and minimize risks.